Breast Cancer Cell Density: Imaging assay of the density- and context-dependence of small molecule perturbagen response in breast cancer cell lines. Dataset 1 of 3: Cell count and normalized growth rate inhibition values. - Dataset (ID:20256)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Replicate | Seeding Density | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Erlotinib | 1 | uM | 8 | 312.50 | 180.33 | 243.00 | 276.75 | 0.8781 | 0.6204 |
| SK-BR-3 | 17-AAG | 0.0031623 | uM | 8 | 312.50 | 180.33 | 286.00 | 276.75 | 1.0334 | 1.1093 |
| SK-BR-3 | 0 | uM | 8 | 312.50 | 180.33 | 518.00 | 276.75 | 1.8717 | 4.5158 | |
| SK-BR-3 | Linsitinib | 1 | uM | 8 | 312.50 | 180.33 | 340.00 | 276.75 | 1.2285 | 1.7906 |
| SK-BR-3 | Erlotinib | 0.031623 | uM | 8 | 312.50 | 180.33 | 383.00 | 276.75 | 1.3839 | 2.3837 |
| SK-BR-3 | Lapatinib | 0.31623 | uM | 8 | 312.50 | 180.33 | 269.00 | 276.75 | 0.9720 | 0.9102 |
| SK-BR-3 | 17-AAG | 0.0001 | uM | 8 | 312.50 | 180.33 | 415.00 | 276.75 | 1.4995 | 2.8530 |
| SK-BR-3 | 0 | uM | 8 | 312.50 | 180.33 | 391.00 | 276.75 | 1.4128 | 2.4988 | |
| SK-BR-3 | 17-AAG | 0.000302 | uM | 8 | 312.50 | 180.33 | 441.00 | 276.75 | 1.5935 | 3.2511 |
| SK-BR-3 | Erlotinib | 10 | uM | 8 | 312.50 | 180.33 | 209.00 | 276.75 | 0.7552 | 0.2697 |
| SK-BR-3 | 17-AAG | 0.001 | uM | 8 | 312.50 | 180.33 | 213.00 | 276.75 | 0.7697 | 0.3092 |
| SK-BR-3 | Lapatinib | 10 | uM | 8 | 312.50 | 180.33 | 163.00 | 276.75 | 0.5890 | -0.1509 |
| SK-BR-3 | 0 | uM | 8 | 312.50 | 180.33 | 348.00 | 276.75 | 1.2575 | 1.8976 | |
| SK-BR-3 | 0 | uM | 8 | 312.50 | 180.33 | 254.00 | 276.75 | 0.9178 | 0.7408 | |
| SK-BR-3 | 17-AAG | 0.000066069 | uM | 8 | 312.50 | 180.33 | 264.00 | 276.75 | 0.9539 | 0.8530 |
| SK-BR-3 | 0 | uM | 8 | 312.50 | 180.33 | 248.00 | 276.75 | 0.8961 | 0.6747 | |
| SK-BR-3 | 0 | uM | 8 | 312.50 | 180.33 | 288.00 | 276.75 | 1.0407 | 1.1332 | |
| SK-BR-3 | 0 | uM | 8 | 312.50 | 180.33 | 216.00 | 276.75 | 0.7805 | 0.3392 | |
| SK-BR-3 | 0 | uM | 8 | 312.50 | 180.33 | 257.00 | 276.75 | 0.9286 | 0.7742 | |
| SK-BR-3 | Erlotinib | 0.01 | uM | 8 | 312.50 | 180.33 | 271.00 | 276.75 | 0.9792 | 0.9332 |
| SK-BR-3 | Erlotinib | 3.1623 | uM | 8 | 312.50 | 180.33 | 316.00 | 276.75 | 1.1418 | 1.4788 |
| SK-BR-3 | 17-AAG | 0.31623 | uM | 8 | 312.50 | 180.33 | 182.00 | 276.75 | 0.6576 | 0.0150 |
| SK-BR-3 | Linsitinib | 19.9526 | uM | 8 | 312.50 | 180.33 | 236.00 | 276.75 | 0.8528 | 0.5455 |
| SK-BR-3 | Linsitinib | 0.01 | uM | 8 | 312.50 | 180.33 | 389.00 | 276.75 | 1.4056 | 2.4699 |
| SK-BR-3 | Linsitinib | 0.031623 | uM | 8 | 312.50 | 180.33 | 351.00 | 276.75 | 1.2683 | 1.9382 |